Halla Group considers $40 mil equity investment in chip parts firm Total acquisition cost for Willbe S&T expected to be about $150 mil
Translated by Ryu Ho-joung 공개 2022-05-24 08:05:13
이 기사는 2022년 05월 24일 08:02 thebell 에 표출된 기사입니다.
Halla Group is considering investing 50 billion won ($39.5 million) in a private equity fund that will acquire South Korea-based semiconductor component maker Willbe S&T.A consortium of Kiwoom Capital and Lotus Private Equity was picked as the preferred buyer for Willbe S&T at the end of April and is currently conducting due diligence. Another private equity firm Dominus Investment also joined the consortium as a co-general partner.
The total acquisition cost for the chip parts firm is expected to be about 190 billion won. The consortium is said to be funding 100 billion won in equity and the remaining 90 billion won through debt financing.
If Halla Group puts 50 billion won into the consortium’s fund, this would make the conglomerate the largest investor in Willbe S&T. Key affiliates under Halla Holdings, the group’s holding company, include auto parts maker Mando Corp and construction company Halla Corp. It is said which of them will invest in Willbe S&T has not determined yet.
Halla Group’s interest in Willbe S&T is part of efforts by the conglomerate to find future growth drivers.
Willbe S&T produces retainer rings used in semiconductor manufacturing devices as well as display parts. It recorded revenue of 64.6 billion won in 2021 on a non-consolidated basis, up 27.5% year-on-year. Operating profit and net profit were 14.4 billion won and 14.7 billion won, respectively, up 51.2% and 61.5% from a year ago. Earnings before interest, tax, depreciation and amortization increased 49% year-on-year to 15 billion won. (Reporting by Gyoung-tae Kim)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- 이엔플러스, 글로벌 셀메이커 방열 소재 사용 승인
- [아시아나 화물사업부 M&A]본입찰 마감, 제주항공 불참
- 크라우드웍스, 비즈니스 특화 소형언어모델 ‘웍스원’ 개발
- [클리니컬 리포트]박셀바이오, '가보지 않은' NK 췌장암 임상 '숨고르기'
- [제일약품의 온코닉테라퓨틱스 첫 '신약']'비상장 바이오벤처' 국산신약, 블록버스터에 도전장
- [Red & Blue]보라티알, 오염수 방류 중단되자 '소금 테마' 주도
- 초격차 저력 삼성바이오로직스 실적 '또 자체기록 경신'
- [Company Watch]'손바뀜 실패' 프리엠스, 매각 완주 가능성은
- [코스닥 MZ 리더가 온다]지배구조 재편 성공한 강원에너지, 성장 발판 마련
- [한경협 파이낸셜 리포트]'돈 굴리기' 보수적 접근, '채권 투자' 집중